MXCT
MaxCyte, Inc.
MXCT offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over MXCT overall, supported by lower modeled downside and stronger modeled upside.
MXCT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
MXCT's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
MXCT PE Valuation
MXCT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
MXCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect MXCT's revenue to grow, with its earnings and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MXCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.25 | +$0.19 |
| Q2 2026 | -$0.32 | +$0.11 |
| Q1 2026 | -$0.36 | +$0.04 |
| Q4 2025 | -$0.42 | -$0.03 |
| Q3 2025 | -$0.44 | -$0.10 |
| Q2 2025 | -$0.43 | -$0.09 |
| Q1 2025 | -$0.40 | -$0.05 |
| Q4 2024 | -$0.39 | -$0.02 |
MXCT is still losing money, but less than at its worst: $0.25 per share over the past year, against $0.44 at its worst in late 2025.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over MXCT on earnings quality, reporting a profit while its opponent remains loss making.
MXCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.2M | +49% |
| Q2 2026 | $7.3M | -15% |
| Q1 2026 | $9.7M | -7.1% |
| Q4 2025 | $7.3M | -16% |
| Q3 2025 | $6.8M | -16% |
| Q2 2025 | $8.5M | -18% |
| Q1 2025 | $10.4M | -8.4% |
| Q4 2024 | $8.7M | -45% |
MXCT's revenue is recovering but still below its 2023 peak: $10M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +148 points |
| Q2 2026 | -141% | +27 points |
| Q1 2026 | -64% | +54 points |
| Q4 2025 | -154% | -5.4 points |
| Q3 2025 | -207% | -35 points |
| Q2 2025 | -167% | -53 points |
| Q1 2025 | -118% | -10 points |
| Q4 2024 | -148% | -97 points |
MXCT's operating margin was −60% last quarter, up 148 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over MXCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over MXCT on profitability, with a higher operating margin.
MXCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | +$2.2M |
| Q2 2026 | -$4.7M | +$5.7M |
| Q1 2026 | -$8.2M | +$6.8M |
| Q4 2025 | -$2.9M | +$5M |
| Q3 2025 | -$7.8M | -$3M |
| Q2 2025 | -$10.4M | -$5.3M |
| Q1 2025 | -$15.1M | -$3.7M |
| Q4 2024 | -$8M | -12010% |
MXCT has burned cash in almost every quarter: −$21M over the past year, against −$41M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over MXCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
MXCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.1% | -3.3M shares |
| 1 year | -2.9% | -3.1M shares |
| 3 years | +0.1% | +88.2K shares |
| 5 years | +22% | +18.8M shares |
| Available history | +80% | +46.1M shares |
MXCT has the edge over UNH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4M |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
MXCT Net Leverage
MXCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
MXCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.2 | Neutral |
| Stochastic | 49.8 | Neutral |
MXCT's weekly RSI is 49 (neutral) and its Stochastic is 50 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
MXCT PE vs Healthcare Sector
MXCT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
MXCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.25 | 4.8% below |
| 20 week MA | $1.23 | 3.3% below |
| 50 week MA | $1.12 | 6.2% above |
| 100 week MA | $1.84 | 35% below |
| 200 week MA | $3.06 | 61% below |
MXCT's trend is mixed: it's above one of its five weekly moving averages, and 61% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over MXCT on trend strength, trading above more of its moving averages.
MXCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.0 | $10.8 | -36% |
| 2022 | $10.8 | $5.01 | -54% |
| 2023 | $5.01 | $4.70 | -6.2% |
| 2024 | $4.70 | $4.13 | -12% |
| 2025 | $4.13 | $1.61 | -61% |
| 2026 YTD | $1.61 | $1.19 | -26% |
MXCT has finished every year since 2021 lower, and it's down 26% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over MXCT on returns for 2026, with the stronger performance.